Table 4. Suitable therapeutic approaches to first-line treatment of H. pylori infection.

Name	Days	Agents	Dosing
Italian TT	1–7	PPI*	b.i.d.
	1–7	Clarithromycin 250–500 mg	b.i.d.
	1–7	Metronidazole 400–500 mg	b.i.d.
French TT	1–7	PPI*	b.i.d.
	1–7	Clarithromycin 500 mg	b.i.d.
	1–7	Amoxicillin 1000 mg	b.i.d.
Sequential therapy	1–5	PPI*	b.i.d.
	1–5	Amoxicillin 1000 mg	b.i.d.
	6–10	PPI*	b.i.d.
	6–10	Clarithromycin 500 mg	b.i.d.
	6–10	Metronidazole 500 mg	b.i.d.
Quadruple therapy	1–7	PPI*	b.i.d.
	1–7	Clarithromycin 250–500 mg	b.i.d.
	1–7	Metronidazole 400 mg	b.i.d.
	1–7	Amoxicillin 1000 mg	b.i.d.

^*Proton pump inhibitor (PPI) dose: esomeprazole 20 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg. TT, triple therapy. Tables 1–4 from Fischbach et al.: S3 guideline on Helicobacter pylori and gastroduodenal ulcer disease of the German Society for Digestive and Metabolic Diseases (Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, DGVS). Z Gastroenterol 2009; 47: 68–102 (with the kind permission of Georg Thieme Verlag, Stuttgart/New York.)